Menopausal hormone therapy shows no added breast cancer risk for BRCA carriers

	Breast Cancer
	The latest breast cancer news from News Medical

	Menopausal hormone therapy shows no added breast cancer risk for BRCA carriers Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

	Dietary restriction boosts antitumour immunity by rewiring T cell metabolism Dietary restriction reshapes CD8+ T cell metabolism by increasing ketone body–driven acetyl-CoA production, preventing terminal exhaustion and enhancing tumour control in mice. This metabolic reprogramming also boosts responsiveness to PD-1 blockade, suggesting a potential strategy to improve cancer immunotherapy.

			Next-generation oral SERD therapy lowers the risk of breast cancer recurrence In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.

			Small molecule discovery could open the door to new class of treatments for hard-to-treat cancers Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer-driving protein long considered impossible to target with drugs - a discovery that could open the door to a new class of treatments for leukemia and other hard-to-treat cancers.

			More AI explanations can reduce accuracy in cancer diagnosis In recent years AI has emerged as a powerful tool for analyzing medical images. Thanks to advances in computing and large medical datasets from which AI can learn, it has proven to be a valuable aid in reading and analyzing patterns in X-rays, MRIs and CT scans, enabling doctors to make better and faster decisions, particularly in the treatment and diagnosis of life-threatening diseases like cancer.

	AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

	Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

	Machine learning models can help diagnose ALS earlier from a blood sample Using machine learning models, researchers at Michigan Medicine have identified a potential way to diagnose amyotrophic lateral sclerosis, or ALS, earlier from a blood sample, a study suggests.

	Acupuncture improves breast cancer survivors' perceived cognitive impairment Real and sham acupuncture were more effective at improving breast cancer survivors' perceived cognitive impairment compared with usual care, while real acupuncture was superior to sham acupuncture in improving objective cognitive function, according to results from the randomized ENHANCE phase II clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

	Wheelchair? Hearing aids? Yes. ‘Disabled?' No way. In her house in Ypsilanti, Michigan, Barbara Meade said, "there are walkers and wheelchairs and oxygen and cannulas all over the place."

	Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of the phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

	AI-driven method uncovers genetic interactions that fuel cancer progression University of South Australia scientists have developed a powerful new way to uncover the genetic interactions that fuel cancer progression, paving the way for earlier and more precise treatments.

	Cleveland Clinic reports promising results for breast cancer vaccine from final Phase 1 data Cleveland Clinic researchers are presenting final Phase 1 data from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

	Metabolic imaging enables early response prediction in bone-dominant metastatic breast cancer A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone receptor-positive (HR+) metastatic breast cancer that has spread primarily or exclusively to the bones.

	Skipping sentinel lymph node biopsy may be safe for some early-stage breast cancer patients Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according to results from the BOOG 2013-08 phase III clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

	Breast arterial calcification on mammograms predicts future heart risk Routine mammograms are a critical tool for breast cancer screening. However, they may also hold crucial, potentially untapped information about a person's risk for cardiovascular disease, the number one cause of death among adults.

	Mobile health intervention improves quality of life for adolescent and young adult breast cancer survivors A mobile health (mHealth) intervention for adolescent and young adult breast cancer survivors that offered tailored support by monitoring electronic patient-reported outcomes (ePROs) significantly improved quality of life and symptoms related to vaginal and arm problems, according to results from a randomized clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

	Preoperative MRI offers no survival benefit for early-stage breast cancer patients Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance imaging (MRI) in addition to diagnostic mammography to determine the extent of their cancer, according to results from the phase III Alliance A011104/ACRIN 6694 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December...

	Atelerix enters agreement with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models Atelerix, a biotech company revolutionizing cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has entered a partnership with Cherry Biotech, a French company specializing in organ-on-chip and organoid technologies for biomedical research.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2025